title: Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial.
abstract: The study sought to compare long-term optical coherence tomography (OCT)-based in-stent vascular response between the abluminal groove-filled biodegradable polymer sirolimus-eluting stent (SES) and the durable polymer everolimus-eluting stent (EES) in the TARGET I trial. The TARGET I trial was a prospective, multicenter, randomized clinical trial which enrolled 458 patients with single de novo lesions treated by abluminal groove-filled biodegradable polymer SES and EES. A subset of 43 patients underwent angiography and OCT examinations at 3 years. All OCT images were analyzed at 0.4 mm intervals. A similar increase in angiographic late lumen loss was observed in SES and EES (from 0.05 ± 0.05 vs. 0.05 ± 0.05 mm [p = 0.84] at 9 months to 0.25 ± 0.37 vs. 0.26 ± 0.19 mm [p = 0.99] at 3 years, respectively), without significant differences at 3 years in mean neointimal thickness of stent struts (SES: 0.13 ± 0.02 mm vs. EES: 0.13 ± 0.02 mm, p = 0.80); mean percentage of covered struts (SES: 99.2 % vs. EES: 99.3 %, p = 0.53), or malapposed strut rates (SES: 0.08 % vs. EES: 0.06 %, p = 0.15). The OCT-based in-stent vascular response evaluation found similar vascular healing for the two studied devices, indicating that the luminal loss in EES from 9 months to 3 years cannot be imputed on its coated biocompatible polymer.
authors.affiliation: Fu Wai Hospital, National Center for Cardiovascular Diseases, No.167, Beilishi Road, Xicheng District, Beijing, 100037, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Xu
authors.affiliation: Nanjing First Hospital, Nanjing Medical University, Nanjing, China. 13770668667@139.com.
authors.forename: Yao-Jun
authors.initials: YJ
authors.lastname: Zhang
authors.affiliation: Fu Wai Hospital, National Center for Cardiovascular Diseases, No.167, Beilishi Road, Xicheng District, Beijing, 100037, China.
authors.forename: Zhong-Wei
authors.initials: ZW
authors.lastname: Sun
authors.affiliation: Fu Wai Hospital, National Center for Cardiovascular Diseases, No.167, Beilishi Road, Xicheng District, Beijing, 100037, China.
authors.forename: Shu-Bin
authors.initials: SB
authors.lastname: Qiao
authors.affiliation: Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Shao-Liang
authors.initials: SL
authors.lastname: Chen
authors.affiliation: Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: Rui-Yan
authors.initials: RY
authors.lastname: Zhang
authors.affiliation: Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Dao-Rong
authors.initials: DR
authors.lastname: Pan
authors.affiliation: Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Si
authors.initials: S
authors.lastname: Pang
authors.affiliation: Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Fu Wai Hospital, National Center for Cardiovascular Diseases, No.167, Beilishi Road, Xicheng District, Beijing, 100037, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Xu
authors.affiliation: Fu Wai Hospital, National Center for Cardiovascular Diseases, No.167, Beilishi Road, Xicheng District, Beijing, 100037, China.
authors.forename: Yue-Jin
authors.initials: YJ
authors.lastname: Yang
authors.affiliation: Columbia University Medical Center, New York, NY, USA.
authors.forename: Martin B
authors.initials: MB
authors.lastname: Leon
authors.affiliation: Fu Wai Hospital, National Center for Cardiovascular Diseases, No.167, Beilishi Road, Xicheng District, Beijing, 100037, China. gaorunlin@citmd.com.
authors.forename: Run-Lin
authors.initials: RL
authors.lastname: Gao
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002681:China; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation*; D011108:Polymers; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011474:Prosthesis Design; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D066253:Vascular Remodeling / Q000187:drug effects; D014945:Wound Healing / Q000187:drug effects
chemical_list: D002317:Cardiovascular Agents; D011108:Polymers; D000068338:Everolimus; D020123:Sirolimus
keywords: Biodegradable polymer; Everolimus-eluting stent; In-stent vascular response; Optical coherence tomography